

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Synthesis of 3-(4-(imidazo [4,5-b]pyridine-2-yl)phenylamino)-2 arylthiazolidin-4-ones and 1-(4-(3H-imidazo[4,5-b]pyridine2-yl)pheylamino)-3-chloro-4-arylazetidid-2-ones.

Dayakar G*, and Sujatha I

Department of chemistry, Kakatiya university , Warangal, A.P-506009.

ABSTRACT

2, 3-Diaminopyrindine (**1**) reacts with 4—bromobenzaldehyde (**2**) and gives 2-(4-bromophenyl)-3H-imidazo[4,5-b]pridine (**3**). The bromo group is substituted by hydrazine hydrate to produce compound (**4**). Then it is condensed with different aldehydes and the product obtained is reacted with thioglycolic acid and chloroacetyl chloride to offer 3-(4-(3H-imidazo[4,5-b]pyridine-2-yl)phenylamino)-2-arylthiazolidin-4-ones (**6a-i**) and 1-(4(3H-imidazo[4,5-b]pyridine-2-yl) phenylamino)-3-chloro-4-arylazetidid-2-ones (**7a-i**) respectively.

Keywords: synthesis, pyridine, hydrazine, thioglycolic acid


**Corresponding author*

INTRODUCTION

2, 3 diaminopyridine and imidazo [4,5-b]pyridines have been proved to be useful precursors for the synthesis of a variety of medicinal agents. The heterocycles derived from these intermediates have recently been evaluated as antagonists of various biological receptors, including angiotensin-II,[1] platelet activating factor (PAF)[2] metabotropic glutamate subtype V[3]. substituted Imidazo [4,5-b]pyridines have also been tested for their potential as anticancer,[4] inotropic,[5] and Selective antihistamine (H1) agents.[6] Imidazo [4,5-b]pyridines derivatives were also reported as Aurora kinases,[7] cyclic PDF inhibitors.[8] Hence, the synthesis of Imidazo [4,5-b]pyridines derivatives is currently of great interest. Various methods [9-16] reported for the synthesis of Imidazo [4,5-b]pyridines were based on cyclocondensation of 2,3 pyridinediamine with Carboxylic acid derivatives or on condensation with aldehydes. Hence, it is imperative to develop a convenient, efficient, and user friendly method for the synthesis of 2-substituted-1H-Imidazo [4,5-b]pyridine.

Nowadays, the organic reactions in aqueous media and EtOH have attracted much attention in Synthetic organic chemistry as water is the most abundant, cheapest, and environmental-friendly Solvent. It also exhibits a unique reactivity and selectivity different from conventional organic solvents. A very diverse range of biological activities are associated with 4-thiazolidinones and 2-Azetidinones. Keeping the conjecture in mind, numerous compounds having moiety are Prepared.[17-20]

Scheme :





EXPERIMENTAL

The IR spectra recorded on brucher-IFS-66 FTIR instrument. 500 Mhz NMR spectra were recorded using tetramethyl silane as an instrument standard in DMSO-d₆. Chemical shifts are expressed in ppm and mass spectrum on a Hewelett Packard mass spectrometer operating at 70ev. The purity of the compounds was checked by TLC and spots were visualized in iodine vapour.

2-(4-bromophenyl)-3H-Imidazo [4,5-b]pyridine(3)

2,3-Diaminopyridine (0.001 m mole) and 4-bromobenzaldehyde (0.001 m mole) in Ethanol containing a few drops of pyridine are refluxed for 5-6 hours. It was then cooled, concentrated and poured into crushed ice and filtered. The solid thus obtained was purified by recrystallization from ethanol.

IR (K Br): 3522.02 cm⁻¹ (NH), 3074.53 cm⁻¹ (C-H aromatic), 1583.56cm⁻¹ (C=N), 1199.72 cm⁻¹ (C-N).

¹ H NMR in DMSO-d₆: 7.75(dd, 4H),8.01 (dd, 1H) 8.80 (d,1H), 9.21 (d, 1H), 9.95(brs, 1H).
MS:274.9(M+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)hydrazine(4)

Compound 2-(4-bromophenyl)-3H-imidazo [4,5-b]pyridine (3) (0.001 m mole) a pinch of PTSA And hydrazine hydrate (0.001 m mole) were taken into a RB flask. The contents were refluxed

For 3-4 hrs. the reaction mixture was washed with ice cold water and the solid obtained was Purified.

IR (K Br) : 3323.35 cm⁻¹, 3280.92 cm⁻¹ (NH), 3024.38 cm⁻¹ (C-H aromatic), 1697.36cm⁻¹ (C=N), 1136.07 cm⁻¹ (C-N).

¹ H NMR in DMSO-d₆: 4.52(drs, 3H),7.73 (dd,4H), 8.08 (dd,1H), 8.84 (d, 1H),9.25 (d, 1H),12.41(brs, 1H)
MS:226.0(M+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-arylidenehydrazines (5a-i)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)hydrazine (**5**) (0.001m mole) and aldehyde (0.001 M mole) in Ethanol containing a few drops of pyridine are refluxed for 5-6 hours. It was then cooled, concentrated and poured into crushed ice and filtered. The solid thus obtained was purified by recrystallization from ethanol.

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-phenylidenehydrazines (5a)

IR (K Br) : 3380.92 cm⁻¹ (NH) , 3184.38 cm⁻¹ (C-H aromatic), 1656.85 cm⁻¹, (C=N),1166.93 cm⁻¹ (C-N).

¹ H NMR in DMSO-d₆ : 7.15-7.31 (m, 6H), 7.61-7.80 (m, 6H), 7.95 (dd, 1H), 8.40 (d, 1H), 9.18 (brs, 1H), 9.50 (brs, 1H)
MS: 313 (m+)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(3-chlorophenylidene)hydrazine (5b)

¹ H NMR in DMSO-d₆ : 7.17-7.32 (m, 6H), 7.63-7.82 (m, 6H), 7.98 (dd, 1H), 8.38 (d, 1H), 9.62 (brs, 1H).
MS: 348 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(4-chlorophenylidene)hydrazine (5c)

¹ H NMR in DMSO-d₆ : 7.16-7.32 (m, 5H), 7.60-7.81 (m, 6H), 7.96 (dd, 1H), 8.40 (d, 1H), 9.20 (brs, 1H), 9.61 (brs 1H)
MS: 348 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(2-chlorophenylidene)hydrazine (5d)

¹ H NMR in DMSO-d₆ : 7.15-7.31 (m, 5H), 7.58-7.80 (m, 6H), 7.75 (dd, 1H), 8.39 (d, 1H), 9.18 (brs, 1H), 9.60 (brs 1H)
MS: 348 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(4-methoxyphenylidene)hydrazine (5e)

¹ H NMR in DMSO-d₆ : 3.82(s, 3H), 7.10-7.30 (m, 5H), 7.64-7.825 (m, 6H), 7.90 (dd, 1H), 8.37 (d, 1H), 9.17 (brs, 1H), 9.60 (brs 1H)
MS: 344 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(3-methoxyphenylidene)hydrazine (5f)

¹ H NMR in DMSO-d₆: 3.82(s, 3H), 7.10-7.30 (m, 5H), 7.64-7.82 (m, 6H), 7.90 (dd, 1H), 8.37 (d, 1H), 9.17 (brs, 1H), 9.60 (brs 1H)
MS: 344 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridine-2-yl)phenyl)-2-(2-methoxyphenylidene)hydrazine(5g)

¹H NMR in DMSO-d₆; 3.80(s, 3H), 7.16-7.33(m, 5H), 7.66-7.84(m, 6H), 7.90 (dd, 1H), 8.39(d, 1H), 9.16(brs, 1H), 9.62(brs, 1H).
MS: 344(m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(2-nitrophenylidene)hydrazine (5h)

¹ H NMR in DMSO-d₆ : 7.26-7.40 (m, 5H), 7.65-7.95 (m, 6H), 7.95 (dd, 1H), 8.35 (d, 1H), 9.20 (brs, 1H), 8.35 (d, 1H), 9.20 (brs 1H), 9.70 (brs 1H) MS: 359 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenyl)-2-(4-nitrophenylidene)hydrazine (5i)

¹ H NMR in DMSO-d₆ : 7.25-7.42 (m, 5H), 7.66-7.96 (m, 6H), 7.98 (dd, 1H), 8.38 (d, 1H), 9.20 (brs, 1H), 7.71 (brs, 1H)
MS: 359 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2-arylthiazolidin-4-one(6a-i)

To a solution of 1-(4-(3H-imidazo[4,5-b]pyridin-2-yl)phenyl)-2-phenylidenehydrazines (**5a**) (0.001 m mole) in absolute ethanol thiglycolic acid (0.001 m mole) and anhydrous zinc chloride were refluxed for 8 hr, concentrated, cooled and poured into crushed ice, and then filtered. The solid obtained was purified by recrystalization.

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2-phenylthiazolidin-4-ones(6a)

IR (K Br) : 3442.06 cm⁻¹ (NH) ; 2924.85 cm⁻¹ (C-H aromatic), 1119.54 cm⁻¹, (C-N) .¹ H NMR in DMSO-d₆ : 3.95 (d, 2H), 5.61 (s, 1H), 7.10 (m, 5H), 7.31 (d, 2H), 7.72 (m, 3H), 7.95 (dd, 1H), 8.40 (d, 1H), 9.19 (brs, 1H), 9.52 (brs, 1H)
MS: 388.6 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(3-chlorophenyl)thiazolidin-4-one(6b)

¹ H NMR in DMSO-d₆ : 3.90 (d, 2H), 5.60 (s, 1H), 7.12 (m, 4H), 7.30 (d, 2H), 7.73 (d, 2H), 7.96 (dd, 1H), 8.41 (d, 1H), 9.20 (brs, 1H), 9.55 (brs, 1H)
MS: 423 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(4-chlorophenyl)thiazolidin-4-one(6c)

¹ H NMR in DMSO-d₆ : 3.92 (d, 2H), 5.62 (s, 1H), 7.13 (m, 4H), 7.32 (d, 2H), 7.74 (d, 2H), 7.96 (dd, 1H), 8.42 (d, 1H), 9.21 (brs, 1H), 9.60 (brs, 1H)
MS: 423 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(2-chlorophenyl)thiazolidin-4-one(6d)

¹H NMR in DMSO-d₆ : 3.96 (d, 2H), 5.61 (s, 1H), 7.14 (m, 4H), 7.32 (d, 2H), 7.75 (d, 2H), 7.96 (dd, 1H), 8.43 (d, 1H), 9.25 (brs, 1H), 9.61 (brs, 1H)
MS: 423 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(4-methoxyphenyl) thiazolidin-4-one(6e)

¹ H NMR in DMSO-d₆ : 3.76 (s, 3H), 3.93 (d, 2H), 5.63 (s, 1H), 7.15 (m, 4H), 7.33 (d, 2H), 7.76 (d, 2H), 7.95 (dd, 1H), 9.25 (brs, 1H), 9.61 (brs, 1H)
MS: 418 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(3-methoxyphenyl)thiazolidin-4-one(6f)

¹ H NMR in DMSO-d₆ : 3.75 (s, 3H), 3.95 (d, 2H), 5.64 (s, 1H), 7.16 (m, 4H), 7.35 (d, 2H), 7.75 (d, 2H), 7.96 (dd, 1H), 8.41 (d, 1H), 9.31 (brs, 1H), 9.60 (brs, 1H)
MS: 418 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(2-methoxyphenyl) thiazolidin-4-one(6g)

¹ H NMR in DMSO-d₆ : 3.78 (s, 3H), 3.98 (d, 2H), 5.65 (s, 1H), 7.17 (m, 4H), 7.36 (d, 2H), 7.74 (d, 2H), 7.95 (dd, 1H), 8.40 (d, 1H), 9.30 (brs, 1H), 9.61 (brs, 1H)
MS: 418 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(2-nitrophenyl)thiazolidin-4-one(6h)

¹ H NMR in DMSO-d₆ : 3.97 (d, 2H), 5.66 (s, 1H), 7.16 (m, 4H), 7.35 (d, 2H), 7.73 (d, 2H), 7.96 (dd, 1H), 7.96 (dd, 1H), 8.41 (d, 1H), 9.31 (brs, 1H), 9.62 (brs, 1H)
MS: 433 (m+1)

3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(4-nitrophenyl)thiazolidin-4-one(6i)

¹ H NMR in DMSO-d₆ : 3.96 (d, 2H), 5.65 (s, 1H), 7.15 (m, 4H), 7.34 (d, 2H), 7.72 (d, 2H), 7.95 (dd, 1H), 8.40 (d, 1H), 9.30 (brs, 1H), 9.62 (brs, 1H)
MS: 433 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4-arylazetid-2-ones(7a-i)

To a solution of 3-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-2(2-nitrophenyl)thiazolidin-4-one (**6**) (0.01 mole) in benzene (50 ml), chloroacetylchloride ((0.02 mole)) and triethylamine (0.02 mole) were added drop wise with constant stirring. The reaction mixture was then refluxed for 6 hr and the excess of benzene was distilled off. Resulting mixture was poured into crushed ice, filtered and the solid obtained was purified by recrystallization from ethanol.

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4-arylazetid-2-one(7a)

IR (K Br) : 3440.01 cm⁻¹ (NH), 2923.74 cm⁻¹ (C-H aromatic), 1126.75 cm⁻¹, (C-N). ¹H NMR in DMSO-d₆ : 5.05 (d, 1H), 5.50 (d, 1H), 7.22 (m, 5H), 7.70 (dd, 4H), 8.00 (dd, 1H), 8.80 (dd, 1H), 9.23 (d, 1H), 9.90 (brs, 1H), 10.30 (brs, 1H)
MS: 390 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(3-chlorophenyl) azetid-2-one(7b)

¹H NMR in DMSO-d₆ : 5.10 (d, 1H), 5.51 (d, 1H), 7.23 (m, 4H), 7.73 (dd, 4H), 8.08 (dd, 1H), 8.82 (dd, 1H), 9.20 (d, 1H), 9.91 (brs, 1H), 10.31 (brs, 1H) MS: 425 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(4-chlorophenyl) azetidin-2-one(7c)

^1H NMR in DMSO- d_6 : 5.06 (d, 1H), 5.52 (d, 1H), 7.24 (m, 4H), 7.74 (dd, 4H), 8.06 (dd, 1H), 8.81 (d, 1H), 9.19 (d, 1H), 9.92 (brs, 1H), 10.30 (brs, 1H)

MS: 425 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(2-chlorophenyl)-azetidin-2-one(7d)

^1H NMR in DMSO- d_6 : 5.08 (d, 1H), 5.55 (d, 1H), 7.25 (m, 4H), 7.75 (dd, 4H), 8.10 (dd, 1H), 8.80 (d, 1H), 9.20 (brs, 1H), 9.90 (brs, 1H), 10.35 (brs, 1H)

MS: 391 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(4-methoxyphenyl)-azetidin-2-ones(7e)

^1H NMR in DMSO- d_6 : 3.80 (s, 3H), 5.10 (d, 1H), 5.56 (d, 1H), 7.24 (m, 4H), 7.76 (dd, 4H), 8.08 (dd, 1H), 8.81 (d, 1H), 9.19 (d, 1H), 9.92 (brs, 1H), 10.40 (brs, 1H)

MS: 421 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(3-methoxyphenyl)-azetidin-2-ones(7f)

^1H NMR in DMSO- d_6 : 3.81 (s, 3H), 5.08 (d, 1H), 5.58 (d, 1H), 7.25 (m, 4H), 7.75 (dd, 4H), 8.10 (dd, 1H), 8.80 (d, 1H), 9.20 (d, 1H), 9.90 (brs, 1H), 10.35 (brs, 1H).

MS: 421 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(2-methoxyphenyl)-azetidin-2-ones(7g)

^1H NMR in DMSO- d_6 : 3.80 (s, 3H), 5.10 (d, 1H), 5.60 (d, 1H), 7.26 (m, 4H), 7.76 (dd, 4H), 8.10 (dd, 1H), 8.81 (d, 1H), 9.20 (d, 1H), 9.92 (brs, 1H), 10.36 (brs, 1H)

MS: 421 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(2-nitrophenyl)-azetidin-2-ones(7h)

^1H NMR in DMSO- d_6 : 5.06 (d, 1H), 5.58 (d, 1H), 7.24 (m, 4H), 7.74 (dd, 4H), 8.08 (dd, 1H), 8.80 (dd, 1H), 9.18 (d, 1H), 9.91 (brs, 1H), 10.32 (brs, 1H)

MS: 436 (m+1)

1-(4-(3H-imidazo [4,5-b]pyridin-2-yl)phenylamino)-3-chloro-4(4-nitrophenyl)-azetidin-2-one(7i)

¹H NMR in DMSO-d₆ : 5.08 (d, 1H), 5.60 (d, 1H), 7.22 (m, 4H), 7.72 (dd, 4H), 8.10 (dd, 1H), 8.82 (dd, 1H), 9.20 (d, 1H), 9.92 (brs, 1H), 10.36 (brs, 1H)

MS: 436 (m+1)

REFERENCES

- [1] Chen ST. Dost, G.(merck) U.S. Patent 1992;5:132-216.
- [2] Weier RM, Khanna IK, Stealey MA, Julien J. (Searle) U.S. Patent 1993;5:262,426,
- [3] Kulkarni SS, Newman AH. Bioorg Med Chem Lett 2007;17:2987.
- [4] Temple C, Rose JD, Comber RN, Rener GA. J Med Chem. 30, 1987, 1746; (b) Temple, C., Jr.: Smith, B.H.:Elliott, R.D.:Montgomery, J.A. J Med Chem. 1973:16:292.
- [5] Barraclough P, et al. J M J Med Chem 1990;33:2231.
- [6] Janseens F, et al. J M J Med Chem 28, 1985, 1943.
- [7] Bavestsias V, Sun C, Bouloc N, Reynisson J, Workman P, Linardopoulos S, McDonald E. Bioorg Med Chem Lett 2007; 17:6567.
- [8] Coates WJ, Connolly B, Dhanak D, Flynn ST, Worby A. J Med Chem 1993;36: 1387.
- [9] Garmise DJ, Komlossy J. J Org Chem 1964;29:3403.
- [10] Dubey PK, Ratnam CV. Ind J Chem 1980;19B:863.
- [11] Dubey PK, et al. Ind J Chem 2004;43B:952.
- [12] Robertson DW, et al. Eur J Med Chem 1986;21:223.
- [13] Savarino P, Carpignano VR, Borda A, Barni E. J Heterocycl Chem 1989;26:289.
- [14] Singh MP, Sasmal S, Lu W, Chatterjee MN. Synthesis 2000;10:1380.
- [15] Ryabukhn SV, Plaskon AS, Volochnyuk DM, Tolmachev AA. Synthesis, 21, 2006, 3715.
- [16] Schiffmann R, Neugebauer A, Klen CD. J Med Chem 2006;49:511.
- [17] Ketan Mistry and Desai K R. Indian J Chem 2006;45B:176.
- [18] Tripti singh, Shalabh Sharma, Srivastava V K and Ashok Kumar. Indian J Chem 2006;45B:1557.
- [19] Tejash Kumar J Shah and Vikas A Desai. Arkivoc 2007;xiv:218.
- [20] Laxminarayana Eppakayala, Narender Atmakuri, Shiva Shankar Sripelly and Thirumala chary Maringanti. Int J App Chem 2008;4(3):237.